Drug Trial Radar · NCT02315066
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Last checked: Nov 19, 2026Latest source record: Apr 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Apr 23, 2015
Primary completion
Nov 12, 2020
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Conditions
- Neoplasms
Interventions
PF-04518600Drug
Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
PF-04518600Drug
Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
PF-04518600 plus PF-05082566Drug
Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
PF-04518600 plus PF-05082566Drug
Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1Time frame: The first 2 cycles of treatment (Day 1 up to Day 28)
- Number of Participants With All-Causality Treatment Emergent Adverse Events(TEAEs) and Serious Adverse Event(SAEs), Treatment-Related TEAEs and SAEs in Part ATime frame: AEs: The informed consent date up to the last dosing date + 28 days or all drug-related toxicities resolved date. SAEs: The informed consent date through first dosing date + 98 days or up to the last dosing date + 60 days, and any post-reporting period.
- Number of Participants With Laboratory Test Abnormalities in Part ATime frame: The first dosing date to the earlier date between the last dosing date + 35 days and the first new anti-cancer therapy date (if applicable)
- Number of Participants With DLTs in Part B1Time frame: The First 2 Cycles of Treatment (Day 1 up to Day 28)
- Number of Participants With All-causality TEAEs and SAEs, and Treatment-Related TEAEs and SAEs in Part BTime frame: AEs: The informed consent date up to the last dosing date + 60 days or all drug-related toxicities resolved date. SAEs: The informed consent date through first dosing date + 98 days or up to the last dosing date + 60 days, and any post-reporting period.
- Number of Participants With Laboratory Test Abnormalities in Part BTime frame: The first dosing date to the earlier date between the last dosing date + 35 days and the first new anti-cancer therapy date (if applicable)
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
LAC+USC Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Ronald Regan Medical Center
Los Angeles, California
UCLA Hematology & Oncology Clinic
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Medical Imaging Center of Southern California, Inc.
Santa Monica, California
Santa Monica UCLA Hematology & Oncology Clinic
Santa Monica, California
UConn Health, Pharmacy
Farmington, Connecticut
UConn Health, Neag Comprehensive Cancer Center
Farmington, Connecticut
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Massachusetts General Hospital (MGH)
Boston, Massachusetts
Brigham & Women's Hospital (BWH)
Boston, Massachusetts
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts
Massachusetts General/Chelsea HealthCare Center
Chelsea, Massachusetts
Mass General/North Shore Center for Outpatient Care
Danvers, Massachusetts
Mass General West
Waltham, Massachusetts
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York
Methodist Hospital-Pathology
Houston, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
University of Washington Medical Center
Seattle, Washington
Groupe hospitalier Pitie Salpetriere
Paris, France
Institut Gustave Roussy
Villejuif, France
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
The Netherlands Cancer Institute
Amsterdam, Netherlands
Slotervaart Hospital/Antoni van Leeuwenhoek
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.